<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02919475</url>
  </required_header>
  <id_info>
    <org_study_id>AE051-G-13-003</org_study_id>
    <nct_id>NCT02919475</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis</brief_title>
  <acronym>MOVE-RA</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, PlacebO-controlled, Parallel-group Study to EValuate the Efficacy and Safety of JTE-051 Administered for 12 Weeks to Subjects With Active Rheumatoid Arthritis (MOVE-RA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akros Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akros Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of&#xD;
      JTE-051 administered for 12 weeks in subjects with active rheumatoid arthritis who are&#xD;
      receiving background non-biologic disease-modifying anti-rheumatic drug therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2016</start_date>
  <completion_date type="Actual">June 25, 2018</completion_date>
  <primary_completion_date type="Actual">June 25, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects Achieving at Least 20% Improvement From Baseline in American College of Rheumatology (ACR) Core Set Measures (ACR20 Response Rate) Compared to Placebo at End-of-treatment (EOT)</measure>
    <time_frame>Up to 12 Weeks</time_frame>
    <description>Percentage of subjects achieving at least 20% improvement from baseline (ACR20) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 20% improvement from baseline in the 3 of the 5 remaining ACR core set measures at EOT (up to Week 12) compared to placebo.&#xD;
The ACR core set measures are:&#xD;
Tender joint count&#xD;
Swollen joint count&#xD;
Subject Assessment of arthritis pain&#xD;
Subject's Global Assessment of disease activity (SGA)&#xD;
Physician's Global Assessment of disease activity (PGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving ACR20 Response Rate Compared to Placebo at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage of subjects achieving at least 20% improvement from baseline (ACR20) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 20% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo.&#xD;
The ACR core set measures are:&#xD;
Tender joint count&#xD;
Swollen joint count&#xD;
Subject Assessment of arthritis pain&#xD;
Subject's Global Assessment of disease activity (SGA)&#xD;
Physician's Global Assessment of disease activity (PGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving ACR50 Response Rate Compared to Placebo at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage of subjects achieving at least 50% improvement from baseline (ACR50) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 50% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo.&#xD;
The ACR core set measures are:&#xD;
Tender joint count&#xD;
Swollen joint count&#xD;
Subject Assessment of arthritis pain&#xD;
Subject's Global Assessment of disease activity (SGA)&#xD;
Physician's Global Assessment of disease activity (PGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving ACR70 Response Rate Compared to Placebo at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage of subjects achieving at least 70% improvement from baseline (ACR70) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 70% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo.&#xD;
The ACR core set measures are:&#xD;
Tender joint count&#xD;
Swollen joint count&#xD;
Subject Assessment of arthritis pain&#xD;
Subject's Global Assessment of disease activity (SGA)&#xD;
Physician's Global Assessment of disease activity (PGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SDAI (Simplified Disease Activity Index) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The SDAI Scores indicate how active a patient's rheumatoid arthritis (RA) is currently. The SDAI is the sum of 5 outcome parameters: tender joint score (0 to 28), swollen joint score (0 to 28), Patient's Global Score of disease activity (0 to 10), Physician's Global Score of disease activity (0 to 10) and C-reactive protein (CRP, 0 to 10).General SDAI Score Interpretation is as follows:&#xD;
0.0 - 3.3 Remission 3.4 - 11.0 Low Activity 11.1 - 26.0 Moderate Activity 26.1 - 86.0 High Activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI (Clinical Disease Activity Index) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The CDAI is a useful clinical composite score for following patients with rheumatoid arthritis (RA). The CDAI is the sum of 4 outcome parameters: tender joint score (0 to 28), swollen joint score (0 to 28), Patient's Global Score of disease activity (0 to 10) and Physician's Global Score of disease activity (0 to 10). The CDAI Score Interpretation is as follows:&#xD;
0 to 2.8: Remission 2.9 to 10: Low Disease Activity 10.1 to 22: Moderate Disease Activity 22.1 to 76: High Disease Activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28-CRP (Disease Activity Score [DAS] Based on High-sensitivity C-reactive Protein [Hs-CRP]) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consists of composite score of following variables: 28 tender joint count (TJC28) ranging from 0 to 28, 28 swollen joint count (SJC28) ranged from 0 to 28, C-reactive protein (CRP) (milligrams per liter) and subject's global assessment of disease activity (SGA) ranging from 0 (no disease activity) to 10 (extremely active disease). DAS28-CRP was calculated using following formula:&#xD;
DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*SGA+0.96.&#xD;
DAS28-CRP ranged from 0.96-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP &lt;2.6.&#xD;
A decrease in DAS28-CRP indicated an improvement in participant's condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HAQ-DI (Health Assessment Questionnaire Disability Index) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] in 8 functional area categories: (1) dressing and grooming; (2) arising; (3) eating; (4) walking; (5) hygiene; (6) reaching; (7) gripping; and (8) performing other daily activities. Scores from each functional area category (total 8 categories) were averaged to calculate the HAQ-DI score, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Treatment-related Adverse Events</measure>
    <time_frame>Up to 16 Weeks</time_frame>
    <description>Subjects in the Safety Population (258, subjects who were randomly assigned to treatment and who received at least one dose of study drug). The number of subjects in the Safety Population is 258 subjects, which is 1 less than the Randomized Population of 259 subjects, since 1 randomized subject did not receive any study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentrations (Ctrough) of JTE-051 in Plasma at Week 12</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>JTE-051 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of study drug by mouth daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JTE-051 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of study drug by mouth daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JTE-051 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of study drug by mouth daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JTE-051 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of study drug by mouth daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One dose of study drug by mouth daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JTE-051</intervention_name>
    <description>Active drug tablets containing JTE-051</description>
    <arm_group_label>JTE-051 Dose 1</arm_group_label>
    <arm_group_label>JTE-051 Dose 2</arm_group_label>
    <arm_group_label>JTE-051 Dose 3</arm_group_label>
    <arm_group_label>JTE-051 Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets identical in appearance to the active drug tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A diagnosis of RA prior to the Screening Visit.&#xD;
&#xD;
          -  Active disease despite ongoing therapy with up to two non-biologic disease-modifying&#xD;
             anti-rheumatic drugs, including methotrexate at both the Screening and Baseline&#xD;
             Visits.&#xD;
&#xD;
          -  Screening hs-CRP ≥1.2 x upper limit of normal (ULN).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior/current exposure to biologic and/or kinase inhibitor therapy.&#xD;
&#xD;
          -  Known history or presence of polyneuropathy of any cause and no presence of clinically&#xD;
             active compression neuropathy, radiculopathy or plexopathy at the Screening Visit.&#xD;
&#xD;
          -  Positive test results for human immunodeficiency (HIV) virus, hepatitis B virus or&#xD;
             hepatitis C (HCV) virus at the Screening Visit.&#xD;
&#xD;
          -  Positive drug of abuse and alcohol test results.&#xD;
&#xD;
          -  History of a clinically-significant infection that required oral antimicrobial or&#xD;
             antiviral therapy within 8 weeks prior to Day 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoshiro Masuda</last_name>
    <role>Study Chair</role>
    <affiliation>Akros Pharma Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Upland</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hendersonville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Plata</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Fernando</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barrio Norte</city>
        <state>Córdoba</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Miguel De Tucumán</city>
        <state>Tucumán</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lom</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevlievo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medellín</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogotá</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexicali</city>
        <state>B.c.</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico</city>
        <state>Mexico City</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Luis Potosí</city>
        <state>SLP</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mérida</city>
        <state>Yucatan</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <state>Masovian</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Białystok</city>
        <state>Podlaskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elbląg</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iaşi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Târgu-Mureş</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kherson</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sumy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaporizhzhia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 27, 2016</study_first_submitted>
  <study_first_submitted_qc>September 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2016</study_first_posted>
  <results_first_submitted>March 25, 2021</results_first_submitted>
  <results_first_submitted_qc>June 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2021</results_first_posted>
  <disposition_first_submitted>November 6, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>November 8, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 12, 2019</disposition_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>JTE-051</keyword>
  <keyword>Active Rheumatoid Arthritis</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 24, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT02919475/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT02919475/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Written informed consent was obtained prior to performing any study-related procedures. A copy of the informed consent was provided to each subject enrolled in this study. To qualify for the study, subjects were required to satisfy defined criteria.</recruitment_details>
      <pre_assignment_details>Following informed consent signing, screening procedures to confirm eligibility were performed.&#xD;
Total screened - 528 subjects&#xD;
Screen failure - 268 subjects&#xD;
Randomized Population - 259 subjects (excluded 1 randomized subject due to site scientific misconduct)&#xD;
Intent-to-Treat Population - 257 subjects (excluded 2 randomized subjects: 1 was not dosed and 1 had no post-dose measurement)&#xD;
Safety Population - 258 subjects (excluded 1 randomized subject: 1 was not dosed)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>JTE-051 50 mg</title>
          <description>JTE-051 50 mg orally once daily for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>JTE-051 100 mg</title>
          <description>JTE-051 100 mg orally once daily for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>JTE-051 150 mg</title>
          <description>JTE-051 150 mg orally once daily for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>JTE-051 200 mg</title>
          <description>JTE-051 200 mg orally once daily for 12 weeks</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Placebo orally once daily for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Dosing</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="38"/>
                <participants group_id="P5" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion/Exclusion Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics results are reported for the Intent-to-Treat (ITT) population: 257 subjects who received at least one dose of JTE-051 or placebo and had at least one post-baseline efficacy assessment during the double-blind treatment period.</population>
      <group_list>
        <group group_id="B1">
          <title>JTE-051 50 mg</title>
          <description>JTE-051 50 mg orally once daily for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>JTE-051 100 mg</title>
          <description>JTE-051 100 mg orally once daily for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>JTE-051 150 mg</title>
          <description>JTE-051 150 mg orally once daily for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>JTE-051 200 mg</title>
          <description>JTE-051 200 mg orally once daily for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Placebo orally once daily for 12 weeks</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="51"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="51"/>
            <count group_id="B5" value="52"/>
            <count group_id="B6" value="257"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="223"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="43"/>
                    <measurement group_id="B6" value="211"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="124"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Achieving at Least 20% Improvement From Baseline in American College of Rheumatology (ACR) Core Set Measures (ACR20 Response Rate) Compared to Placebo at End-of-treatment (EOT)</title>
        <description>Percentage of subjects achieving at least 20% improvement from baseline (ACR20) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 20% improvement from baseline in the 3 of the 5 remaining ACR core set measures at EOT (up to Week 12) compared to placebo.&#xD;
The ACR core set measures are:&#xD;
Tender joint count&#xD;
Swollen joint count&#xD;
Subject Assessment of arthritis pain&#xD;
Subject's Global Assessment of disease activity (SGA)&#xD;
Physician's Global Assessment of disease activity (PGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)</description>
        <time_frame>Up to 12 Weeks</time_frame>
        <population>Subjects in the Intent-to-Treat (ITT) population (subjects who received at least one dose of JTE-051 or placebo, and had at least one post-baseline efficacy assessment during the double-blind treatment period) with available efficacy assessment(s) results at EOT (up to Week 12).</population>
        <group_list>
          <group group_id="O1">
            <title>JTE-051 50 mg</title>
            <description>JTE-051 50 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>JTE-051 100 mg</title>
            <description>JTE-051 100 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>JTE-051 150 mg</title>
            <description>JTE-051 150 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>JTE-051 200 mg</title>
            <description>JTE-051 200 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving at Least 20% Improvement From Baseline in American College of Rheumatology (ACR) Core Set Measures (ACR20 Response Rate) Compared to Placebo at End-of-treatment (EOT)</title>
          <description>Percentage of subjects achieving at least 20% improvement from baseline (ACR20) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 20% improvement from baseline in the 3 of the 5 remaining ACR core set measures at EOT (up to Week 12) compared to placebo.&#xD;
The ACR core set measures are:&#xD;
Tender joint count&#xD;
Swollen joint count&#xD;
Subject Assessment of arthritis pain&#xD;
Subject's Global Assessment of disease activity (SGA)&#xD;
Physician's Global Assessment of disease activity (PGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)</description>
          <population>Subjects in the Intent-to-Treat (ITT) population (subjects who received at least one dose of JTE-051 or placebo, and had at least one post-baseline efficacy assessment during the double-blind treatment period) with available efficacy assessment(s) results at EOT (up to Week 12).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.842</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.841</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.842</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving ACR20 Response Rate Compared to Placebo at Week 12</title>
        <description>Percentage of subjects achieving at least 20% improvement from baseline (ACR20) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 20% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo.&#xD;
The ACR core set measures are:&#xD;
Tender joint count&#xD;
Swollen joint count&#xD;
Subject Assessment of arthritis pain&#xD;
Subject's Global Assessment of disease activity (SGA)&#xD;
Physician's Global Assessment of disease activity (PGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)</description>
        <time_frame>Week 12</time_frame>
        <population>Subjects in the ITT population (subjects who received at least one dose of JTE-051 or placebo, and had at least one post-baseline efficacy assessment during the double-blind treatment period) with available efficacy assessment(s) results at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>JTE-051 50 mg</title>
            <description>JTE-051 50 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>JTE-051 100 mg</title>
            <description>JTE-051 100 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>JTE-051 150 mg</title>
            <description>JTE-051 150 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>JTE-051 200 mg</title>
            <description>JTE-051 200 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving ACR20 Response Rate Compared to Placebo at Week 12</title>
          <description>Percentage of subjects achieving at least 20% improvement from baseline (ACR20) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 20% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo.&#xD;
The ACR core set measures are:&#xD;
Tender joint count&#xD;
Swollen joint count&#xD;
Subject Assessment of arthritis pain&#xD;
Subject's Global Assessment of disease activity (SGA)&#xD;
Physician's Global Assessment of disease activity (PGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)</description>
          <population>Subjects in the ITT population (subjects who received at least one dose of JTE-051 or placebo, and had at least one post-baseline efficacy assessment during the double-blind treatment period) with available efficacy assessment(s) results at Week 12.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.832</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.682</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.665</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving ACR50 Response Rate Compared to Placebo at Week 12</title>
        <description>Percentage of subjects achieving at least 50% improvement from baseline (ACR50) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 50% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo.&#xD;
The ACR core set measures are:&#xD;
Tender joint count&#xD;
Swollen joint count&#xD;
Subject Assessment of arthritis pain&#xD;
Subject's Global Assessment of disease activity (SGA)&#xD;
Physician's Global Assessment of disease activity (PGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)</description>
        <time_frame>Week 12</time_frame>
        <population>Subjects in the ITT population (subjects who received at least one dose of JTE-051 or placebo, and had at least one post-baseline efficacy assessment during the double-blind treatment period) with available efficacy assessment(s) results at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>JTE-051 50 mg</title>
            <description>JTE-051 50 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>JTE-051 100 mg</title>
            <description>JTE-051 100 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>JTE-051 150 mg</title>
            <description>JTE-051 150 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>JTE-051 200 mg</title>
            <description>JTE-051 200 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving ACR50 Response Rate Compared to Placebo at Week 12</title>
          <description>Percentage of subjects achieving at least 50% improvement from baseline (ACR50) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 50% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo.&#xD;
The ACR core set measures are:&#xD;
Tender joint count&#xD;
Swollen joint count&#xD;
Subject Assessment of arthritis pain&#xD;
Subject's Global Assessment of disease activity (SGA)&#xD;
Physician's Global Assessment of disease activity (PGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)</description>
          <population>Subjects in the ITT population (subjects who received at least one dose of JTE-051 or placebo, and had at least one post-baseline efficacy assessment during the double-blind treatment period) with available efficacy assessment(s) results at Week 12.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.999</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.627</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.794</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.453</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving ACR70 Response Rate Compared to Placebo at Week 12</title>
        <description>Percentage of subjects achieving at least 70% improvement from baseline (ACR70) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 70% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo.&#xD;
The ACR core set measures are:&#xD;
Tender joint count&#xD;
Swollen joint count&#xD;
Subject Assessment of arthritis pain&#xD;
Subject's Global Assessment of disease activity (SGA)&#xD;
Physician's Global Assessment of disease activity (PGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)</description>
        <time_frame>Week 12</time_frame>
        <population>Subjects in the ITT population (subjects who received at least one dose of JTE-051 or placebo, and had at least one post-baseline efficacy assessment during the double-blind treatment period) with available efficacy assessment(s) results at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>JTE-051 50 mg</title>
            <description>JTE-051 50 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>JTE-051 100 mg</title>
            <description>JTE-051 100 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>JTE-051 150 mg</title>
            <description>JTE-051 150 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>JTE-051 200 mg</title>
            <description>JTE-051 200 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving ACR70 Response Rate Compared to Placebo at Week 12</title>
          <description>Percentage of subjects achieving at least 70% improvement from baseline (ACR70) in tender and swollen joint counts (ACR core set measures 1 and 2) and at least 70% improvement from baseline in the 3 of the 5 remaining ACR core set measures at Week 12 compared to placebo.&#xD;
The ACR core set measures are:&#xD;
Tender joint count&#xD;
Swollen joint count&#xD;
Subject Assessment of arthritis pain&#xD;
Subject's Global Assessment of disease activity (SGA)&#xD;
Physician's Global Assessment of disease activity (PGA)&#xD;
Health Assessment Questionnaire Disability Index (HAQ-DI)&#xD;
Acute Phase Reactant (i.e., hs-CRP - high sensitivity C-reactive protein)</description>
          <population>Subjects in the ITT population (subjects who received at least one dose of JTE-051 or placebo, and had at least one post-baseline efficacy assessment during the double-blind treatment period) with available efficacy assessment(s) results at Week 12.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.113</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.056</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.035</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SDAI (Simplified Disease Activity Index) at Week 12</title>
        <description>The SDAI Scores indicate how active a patient's rheumatoid arthritis (RA) is currently. The SDAI is the sum of 5 outcome parameters: tender joint score (0 to 28), swollen joint score (0 to 28), Patient's Global Score of disease activity (0 to 10), Physician's Global Score of disease activity (0 to 10) and C-reactive protein (CRP, 0 to 10).General SDAI Score Interpretation is as follows:&#xD;
0.0 - 3.3 Remission 3.4 - 11.0 Low Activity 11.1 - 26.0 Moderate Activity 26.1 - 86.0 High Activity</description>
        <time_frame>Week 12</time_frame>
        <population>Subjects in the ITT population (subjects who received at least one dose of JTE-051 or placebo, and had at least one post-baseline efficacy assessment during the double-blind treatment period) with available efficacy assessment(s) results at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>JTE-051 50 mg</title>
            <description>JTE-051 50 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>JTE-051 100 mg</title>
            <description>JTE-051 100 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>JTE-051 150 mg</title>
            <description>JTE-051 150 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>JTE-051 200 mg</title>
            <description>JTE-051 200 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SDAI (Simplified Disease Activity Index) at Week 12</title>
          <description>The SDAI Scores indicate how active a patient's rheumatoid arthritis (RA) is currently. The SDAI is the sum of 5 outcome parameters: tender joint score (0 to 28), swollen joint score (0 to 28), Patient's Global Score of disease activity (0 to 10), Physician's Global Score of disease activity (0 to 10) and C-reactive protein (CRP, 0 to 10).General SDAI Score Interpretation is as follows:&#xD;
0.0 - 3.3 Remission 3.4 - 11.0 Low Activity 11.1 - 26.0 Moderate Activity 26.1 - 86.0 High Activity</description>
          <population>Subjects in the ITT population (subjects who received at least one dose of JTE-051 or placebo, and had at least one post-baseline efficacy assessment during the double-blind treatment period) with available efficacy assessment(s) results at Week 12.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.14" spread="15.437"/>
                    <measurement group_id="O2" value="-21.68" spread="13.275"/>
                    <measurement group_id="O3" value="-19.41" spread="16.446"/>
                    <measurement group_id="O4" value="-19.97" spread="14.244"/>
                    <measurement group_id="O5" value="-17.66" spread="16.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI (Clinical Disease Activity Index) at Week 12</title>
        <description>The CDAI is a useful clinical composite score for following patients with rheumatoid arthritis (RA). The CDAI is the sum of 4 outcome parameters: tender joint score (0 to 28), swollen joint score (0 to 28), Patient's Global Score of disease activity (0 to 10) and Physician's Global Score of disease activity (0 to 10). The CDAI Score Interpretation is as follows:&#xD;
0 to 2.8: Remission 2.9 to 10: Low Disease Activity 10.1 to 22: Moderate Disease Activity 22.1 to 76: High Disease Activity</description>
        <time_frame>Week 12</time_frame>
        <population>Subjects in the ITT population (subjects who received at least one dose of JTE-051 or placebo, and had at least one post-baseline efficacy assessment during the double-blind treatment period) with available efficacy assessment(s) results at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>JTE-051 50 mg</title>
            <description>JTE-051 50 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>JTE-051 100 mg</title>
            <description>JTE-051 100 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>JTE-051 150 mg</title>
            <description>JTE-051 150 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>JTE-051 200 mg</title>
            <description>JTE-051 200 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI (Clinical Disease Activity Index) at Week 12</title>
          <description>The CDAI is a useful clinical composite score for following patients with rheumatoid arthritis (RA). The CDAI is the sum of 4 outcome parameters: tender joint score (0 to 28), swollen joint score (0 to 28), Patient's Global Score of disease activity (0 to 10) and Physician's Global Score of disease activity (0 to 10). The CDAI Score Interpretation is as follows:&#xD;
0 to 2.8: Remission 2.9 to 10: Low Disease Activity 10.1 to 22: Moderate Disease Activity 22.1 to 76: High Disease Activity</description>
          <population>Subjects in the ITT population (subjects who received at least one dose of JTE-051 or placebo, and had at least one post-baseline efficacy assessment during the double-blind treatment period) with available efficacy assessment(s) results at Week 12.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.76" spread="14.768"/>
                    <measurement group_id="O2" value="-22.40" spread="13.469"/>
                    <measurement group_id="O3" value="-21.02" spread="16.153"/>
                    <measurement group_id="O4" value="-21.24" spread="14.208"/>
                    <measurement group_id="O5" value="-17.19" spread="15.548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28-CRP (Disease Activity Score [DAS] Based on High-sensitivity C-reactive Protein [Hs-CRP]) at Week 12</title>
        <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consists of composite score of following variables: 28 tender joint count (TJC28) ranging from 0 to 28, 28 swollen joint count (SJC28) ranged from 0 to 28, C-reactive protein (CRP) (milligrams per liter) and subject's global assessment of disease activity (SGA) ranging from 0 (no disease activity) to 10 (extremely active disease). DAS28-CRP was calculated using following formula:&#xD;
DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*SGA+0.96.&#xD;
DAS28-CRP ranged from 0.96-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP &lt;2.6.&#xD;
A decrease in DAS28-CRP indicated an improvement in participant's condition.</description>
        <time_frame>Week 12</time_frame>
        <population>Subjects in the ITT population (subjects who received at least one dose of JTE-051 or placebo, and had at least one post-baseline efficacy assessment during the double-blind treatment period) with available efficacy assessment(s) results at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>JTE-051 50 mg</title>
            <description>JTE-051 50 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>JTE-051 100 mg</title>
            <description>JTE-051 100 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>JTE-051 150 mg</title>
            <description>JTE-051 150 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>JTE-051 200 mg</title>
            <description>JTE-051 200 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-CRP (Disease Activity Score [DAS] Based on High-sensitivity C-reactive Protein [Hs-CRP]) at Week 12</title>
          <description>Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consists of composite score of following variables: 28 tender joint count (TJC28) ranging from 0 to 28, 28 swollen joint count (SJC28) ranged from 0 to 28, C-reactive protein (CRP) (milligrams per liter) and subject's global assessment of disease activity (SGA) ranging from 0 (no disease activity) to 10 (extremely active disease). DAS28-CRP was calculated using following formula:&#xD;
DAS28-CRP=0.56*square root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural log(CRP+1)+0.014*SGA+0.96.&#xD;
DAS28-CRP ranged from 0.96-9.4, where lower scores indicated less disease activity and remission is DAS28-CRP &lt;2.6.&#xD;
A decrease in DAS28-CRP indicated an improvement in participant's condition.</description>
          <population>Subjects in the ITT population (subjects who received at least one dose of JTE-051 or placebo, and had at least one post-baseline efficacy assessment during the double-blind treatment period) with available efficacy assessment(s) results at Week 12.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="1.039"/>
                    <measurement group_id="O2" value="-1.23" spread="0.979"/>
                    <measurement group_id="O3" value="-1.03" spread="1.123"/>
                    <measurement group_id="O4" value="-1.10" spread="0.987"/>
                    <measurement group_id="O5" value="-0.98" spread="1.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HAQ-DI (Health Assessment Questionnaire Disability Index) at Week 12</title>
        <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] in 8 functional area categories: (1) dressing and grooming; (2) arising; (3) eating; (4) walking; (5) hygiene; (6) reaching; (7) gripping; and (8) performing other daily activities. Scores from each functional area category (total 8 categories) were averaged to calculate the HAQ-DI score, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.</description>
        <time_frame>Week 12</time_frame>
        <population>Subjects in the ITT population (subjects who received at least one dose of JTE-051 or placebo, and had at least one post-baseline efficacy assessment during the double-blind treatment period) with available efficacy assessment(s) results at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>JTE-051 50 mg</title>
            <description>JTE-051 50 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>JTE-051 100 mg</title>
            <description>JTE-051 100 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>JTE-051 150 mg</title>
            <description>JTE-051 150 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>JTE-051 200 mg</title>
            <description>JTE-051 200 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HAQ-DI (Health Assessment Questionnaire Disability Index) at Week 12</title>
          <description>The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty [0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)] in 8 functional area categories: (1) dressing and grooming; (2) arising; (3) eating; (4) walking; (5) hygiene; (6) reaching; (7) gripping; and (8) performing other daily activities. Scores from each functional area category (total 8 categories) were averaged to calculate the HAQ-DI score, which ranged from 0 (no disability) to 3 (severe disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.</description>
          <population>Subjects in the ITT population (subjects who received at least one dose of JTE-051 or placebo, and had at least one post-baseline efficacy assessment during the double-blind treatment period) with available efficacy assessment(s) results at Week 12.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.600"/>
                    <measurement group_id="O2" value="-0.71" spread="0.629"/>
                    <measurement group_id="O3" value="-0.60" spread="0.620"/>
                    <measurement group_id="O4" value="-0.80" spread="0.727"/>
                    <measurement group_id="O5" value="-0.47" spread="0.616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Treatment-related Adverse Events</title>
        <description>Subjects in the Safety Population (258, subjects who were randomly assigned to treatment and who received at least one dose of study drug). The number of subjects in the Safety Population is 258 subjects, which is 1 less than the Randomized Population of 259 subjects, since 1 randomized subject did not receive any study drug.</description>
        <time_frame>Up to 16 Weeks</time_frame>
        <population>Subjects in the Safety Population (258, subjects who were randomly assigned to treatment and who received at least one dose of study drug). The number of subjects in the Safety Population is 258 subjects, which is 1 less than the Randomized Population of 259 subjects, since 1 randomized subject did not receive any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>JTE-051 50 mg</title>
            <description>JTE-051 50 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>JTE-051 100 mg</title>
            <description>JTE-051 100 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>JTE-051 150 mg</title>
            <description>JTE-051 150 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>JTE-051 200 mg</title>
            <description>JTE-051 200 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Treatment-related Adverse Events</title>
          <description>Subjects in the Safety Population (258, subjects who were randomly assigned to treatment and who received at least one dose of study drug). The number of subjects in the Safety Population is 258 subjects, which is 1 less than the Randomized Population of 259 subjects, since 1 randomized subject did not receive any study drug.</description>
          <population>Subjects in the Safety Population (258, subjects who were randomly assigned to treatment and who received at least one dose of study drug). The number of subjects in the Safety Population is 258 subjects, which is 1 less than the Randomized Population of 259 subjects, since 1 randomized subject did not receive any study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Number of subjects with TEAEs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number of subjects with no TEAEs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Concentrations (Ctrough) of JTE-051 in Plasma at Week 12</title>
        <time_frame>Week 12</time_frame>
        <population>Subjects in the Pharmacokinetic (PK) population (received at least one dose of JTE-051 and have at least one usable JTE-051 plasma concentration measurement) with available trough plasma concentrations of JTE-051 at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>JTE-051 50 mg</title>
            <description>JTE-051 50 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>JTE-051 100 mg</title>
            <description>JTE-051 100 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>JTE-051 150 mg</title>
            <description>JTE-051 150 mg orally once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>JTE-051 200 mg</title>
            <description>JTE-051 200 mg orally once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Concentrations (Ctrough) of JTE-051 in Plasma at Week 12</title>
          <population>Subjects in the Pharmacokinetic (PK) population (received at least one dose of JTE-051 and have at least one usable JTE-051 plasma concentration measurement) with available trough plasma concentrations of JTE-051 at Week 12.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119" spread="96.9"/>
                    <measurement group_id="O2" value="178" spread="156"/>
                    <measurement group_id="O3" value="312" spread="252"/>
                    <measurement group_id="O4" value="354" spread="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 16 weeks</time_frame>
      <desc>The Safety Population (258, subjects who were randomly assigned to treatment and who received at least one dose of study drug) was used for safety analysis. The number of subjects in the Safety Population is 258 subjects, which is 1 less than the Randomized Population of 259 subjects, since 1 randomized subject did not receive any study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>JTE-051 50 mg</title>
          <description>JTE-051 50 mg orally once daily for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>JTE-051 100 mg</title>
          <description>JTE-051 100 mg orally once daily for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>JTE-051 150 mg</title>
          <description>JTE-051 150 mg orally once daily for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>JTE-051 200 mg</title>
          <description>JTE-051 200 mg orally once daily for 12 weeks</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo orally once daily for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain/Diffused abdominal pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cellulitis/Cellulitis in right hand</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pneumonia/Bilateral pneumonia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>This serious adverse event resulted in death (assessed as not related).</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis/Exacerbation of rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia/Sleep Disorders: Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="51"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review results communications at least 60 days prior to public release. The sponsor will have a review period of 60 days and can embargo communications regarding trial results for an additional period of 60 days from the end of sponsor review period. The sponsor may require removal of any and all confidential information (other than study results) in the communication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>None reported.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kazuhiro Okamiya</name_or_title>
      <organization>Akros Pharma Inc.</organization>
      <phone>609-919-6123</phone>
      <email>okamiya@akrospharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

